---
figid: PMC9278337__ytac201f4
pmcid: PMC9278337
image_filename: ytac201f4.jpg
figure_link: /pmc/articles/PMC9278337/figure/ytac201-F4/
number: Figure 4
figure_title: ''
caption: The REVIVE acronym can be used to support the identification of patients
  eligible for dual pathway inhibition. CAD, coronary artery disease; eGFR, estimated
  glomerular filtration rate; MI, myocardial infarction; PAD, peripheral artery disease.
article_title: 'Clinical experience with dual pathway inhibition therapy: case series
  and mini review.'
citation: Tobias Geisler, et al. Eur Heart J Case Rep. 2022 Jul;6(7):ytac201.
year: '2022'

doi: 10.1093/ehjcr/ytac201
journal_title: 'European Heart Journal: Case Reports'
journal_nlm_ta: Eur Heart J Case Rep
publisher_name: Oxford University Press

keywords:
- dual pathway inhibition
- antithrombotic therapy
- rivaroxaban
- coronary artery disease
- peripheral artery disease
- case report

---
